Betta Pharmaceuticals and Shengsi Biotech have reached a strategic cooperation and obtained exclusive distribution rights for the FRSW117 product in the Greater China region
I'm PortAI, I can summarize articles.
Beta Pharma has reached a strategic cooperation with Jiangsu Shengsi Bio and Hangzhou Shengsi Bio, signing a framework agreement. Beta Pharma will support Shengsi Bio in research and development, clinical trials, and production. Beta Pharma has obtained the exclusive distribution rights for FRSW117 in the Greater China region. This cooperation will help expand the recombinant coagulation factor market, aligning with the company's development strategy, but it will not have a significant impact on the operating results for the year 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments